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ABSTRACT: Over the past two decades, public interest in the basic biological processes 
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describe the process as the ‗biomedicalization of aging‘. In this paper, we argue that 
contemporary biogerontology, an important sub-field of gerontology that could be construed 
as the primary actor in the process of ‗biomedicalization‘, should be regarded instead as 
advancing a critique of biomedicine. We then provide a genealogy of the critique and close 
the argument by pointing to sources of uncertainty within biogerontology which should be 
taken into account in any further studies of the relationship between biology, medicine and 
the lives of older people. 
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AGEING BETWEEN GERONTOLOGY AND BIOMEDICINE 
 
 
Introduction 
Over the past two decades, interest in the basic biological processes underlying the 
phenomenon of ‗ageing‘ has grown considerably. The emergence of the so-called ‗anti-
ageing‘ movement and the controversies surrounding its promises to extend human longevity 
have captured the attention of the British and American public, but so have the more sober 
assessments presented in popular books such as Leonard Hayflick‘s How and Why We Age 
(1994) and Thomas Kirkwood‘s The End of Age: The Science of Human Aging (1999). This 
interest has motivated both consultations on public attitudes toward research into the causes 
of ageing (Alliance for Aging Research, 2005; MORI, 2006) and political interventions such 
as the White House Conference on Aging (2005) and the House of Lords Report on Ageing 
(2005). These developments have been accompanied by an intensification of research on the 
biology of ageing, and the therapeutic value of a number of biomolecules characterised 
during the course of such research is currently being tested in animal and human trials. 
Lastly, clinicians would appear to be willing increasingly to provide these and other life-
extending treatments to older individuals. This entire situation has captured the attention of 
social scientists, many of whom refer to the ‗biomedicalization of aging‘.  
 
Estes and Binney (1989) first coined the phrase ‗biomedicalization of aging‘ as a label for the 
processes whereby ageing comes to be defined as a matter of ‗biomedical‘ interest, processes 
which would appear today to be intensifying and be increasingly associated with the 
reorganisation of health care around technological intervention and the modes of prevention 
and consumption (Clarke et al., 2003; see also Kaufman et al., 2004). Contemporary 
biogerontology, a subfield of gerontology that is simultaneously engaged in the biomolecular 
and biodemographic characterisation of the processes associated with the development of the 
individual from birth to death, presents however a paradox.
1
 One of its distinctive claims is 
that it provides an alternative model for understanding those diseases that are commonly 
associated with advanced age, such as cardio-vascular disease, cancer and dementia. Rather 
than pursuing the disease-specific model that has been deployed within many other branches 
of the biomedical enterprise, biogerontologists argue that increases in health and longevity 
are more likely to be achieved by focusing research on the common biological basis of all 
those diseases that would seem to characterise the lives of older people. Furthermore, in 
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reconstructing these diseases as part of a wider set of ‗degenerative diseases‘ that are only 
connected contingently to the organism‘s chronological age, biogerontologists would appear 
to call into question the status of ageing as a biological process. In other words, the 
development of biogerontology seems to undermine the possibility of any straightforward 
conjunction of biology and medicine which the phrase ‗biomedicalization of aging‘ conjures 
almost by definition. In drawing attention to this paradox, we follow Keating and Cambrosio 
(2003) and their definition of biomedicine as a set of practices that was established during the 
second half of the twentieth century and that has organised the relationship between the 
laboratory and the clinic by means of hybrid ‗bio-clinical‘ entities. Viewed from this 
perspective, biomedicine is less the systematic application of biological standards and 
products in clinical work (Canguilhem, 1991), than it is a set of conventions that are specific 
to work on particular diseases and enable the coordination of bench and bedside within these 
so delimited domains alone. 
 
In this paper, we articulate this counter-intuitive understanding of biogerontology by first 
exploring the conceptual presuppositions of recent proposals that have emerged from within 
biogerontology to reorganise not just gerontological research, but biomedical research more 
generally. We then offer a genealogy of the situation by turning to the middle decades of the 
twentieth century, when gerontology first gained institutional recognition and the biology of 
ageing was a domain contested between those who argued for a ‗basic‘ approach and those 
who proposed to focus on the differences between ‗normal‘ and ‗pathological‘ ageing. We 
then consider how the latter approach came to dominate the organisation of gerontological 
research in both the United Kingdom and the United States, but for very different reasons, 
and how it eventually was embedded in the activities of the National Institute of Aging 
(NIA). We then trace how the NIA‘s blue-print for research into the causes and treatment of 
ageing initiated a transatlantic, biogerontological critique of biomedicine. Our aim is to 
establish that the development of biogerontology contrasts sharply with the many successful 
relationships that have been established between the laboratory and the clinic by means of 
mediating, hybrid versions of the ‗normal‘ and the ‗pathological‘. If, as Boltanski and 
Thévenot (1999) argue, ‗the less pure a situation is (in the sense that it contains objects from 
different worlds), the easier it is to denounce it‘ (374), biogerontology has harnessed the 
internal tensions of biomedicine, seeking to construct a field of action whereby the historical 
opposition of biomedicine and public health no longer obtains and the laboratory, 
preventative medicine and health maintenance programmes can be integrated seamlessly. In 
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the concluding section of this paper, we point however towards some important sources of 
uncertainty within the biogerontogical project. 
 
Biogerontology and biomedicine 
In past decade, the organisation of gerontological research has gained wide political 
recognition. In the United States, for example, a group of biogerontologists and policy 
makers who were attending the White House Conference on Aging (2005) have drawn 
attention to the minute proportion of the annual budgetary allocation for the National 
Institutes of Health that is dedicated to understanding the basic biology of ageing, and have 
called on legislators to reconsider the situation because ‗the aging research field [is] on the 
threshold of a new way of thinking – shifting from a focus on specific age related illnesses to 
a search for an understanding of aging itself (Alliance for Aging Research, 2005: 4). In the 
United Kingdom, the Science and Technology Committee of the House of Lords, has 
advanced a similar argument, noting that ‗most of the research on ageing and health ... is 
focused on specific diseases and medical conditions for which age is the single largest risk 
factor‘ and then bemoaning the paucity of support for much more promising programmes of 
research on the ‗basic processes of ageing‘ (House of Lords, 2005: 103). 
  
The focal point of these arguments about the current organisation of gerontological research 
and its limitations is the dependence on clinical definitions of those diseases most commonly 
associated with old age. According to the authors of a position statement on health promotion 
and disease prevention in the twenty-first century (Butler et al., 2008), such dependence is 
troubling because it is an effect of an anatomical division of the body that was forged in the 
nineteenth century and no longer provides a useful way to understand disease. The clinical 
worldview, these authors maintain, was well-suited to pathologies characterised by discrete 
and specific aetiologies, but is inadequate to address the chronic, long-term illnesses of the 
late twentieth and early twenty-first centuries. The protracted temporal unfolding of these 
illnesses is so nearly coterminous with ageing that it unsettles the epistemic pairing of the 
‗normal‘ and the ‗pathological‘ that underpins clinical perspective on ageing. Furthermore, 
this pairing assumes that the two states can be situated proximally and intervened upon 
directly, but this obscures understanding of the diverse and complex processes involved in the 
declining functional capacities of the organism such that the perspectives of the laboratory 
and clinic must be integrated with programmes of health screening and maintenance. A 
further criticism of biomedical research is that, by relying on methodological and 
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epistemological structures that are wholly incommensurable with the phenomenon studied, it 
cannot but fail to deliver effective treatments for those pathological states commonly 
associated with old age. As the House of Lords (2006a) notes, ‗generic research into the 
process of ageing ... may be ‗the most direct route to developing novel interventions and 
therapies‖. In sum, the charge is that current organisation of biomedicine may serve many 
clinicians and researchers well, but it fails to secure health and longevity. 
 
At the same time, the biogerontological critique of biomedicine also aims to redraw the 
contours of the relationship between the biology, medicine and society. As the following 
extract from an interview with a biogerontologist intimates, what is required is a wholly new 
approach to disease.
2
 Having been asked about his expertise, this biogerontologist 
foregrounds the issue of normal ageing:  
[My] scientific interest is to explain the occurrence of age associated diseases. 
Some people call that ageing, some people call that normal ageing, [and] some 
people say it‘s different from normal ageing. I don‘t make a distinction between 
them. 
When pressed on the importance attached today to research on the causes of Alzheimer‘s 
Disease (AD) as answer to the problems posed by old age, this biogerontologist adds:  
What‘s behind, let‘s say the senile muscle, is of equal importance ... because 
people can‘t go out any more and they suffer from it. What‘s normal? There‘s 
nothing like normal ageing. 
What is important, according to this biogerontologist, is a historical disjunction between the 
genome and the environment to which the genome is exposed: 
[We] were not meant to live longer than forty years, and the system is optimised 
in an environment like Africa. But now we don‘t live in Africa. ... [Our] life 
history is ... the result of ... an old, optimised genome ... now ... exposed under 
modern, affluent conditions. But it‘s not meant to be ... it‘s not meant to be 
exposed under these conditions.  
From this perspective, normality is a historically specific discrimination of little biological 
significance, at least insofar as biology is equated with attention to the evolutionary dynamics 
shaping the life course of the organism. This argument has gained considerable momentum in 
the context of what has become known as ‗evolutionary medicine‘ (Nesse & Williams, 1996) 
and encapsulates a more general approach that undermines the long-established recourse to a 
categorical contrast between normal and pathological states whereby problems that could be 
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regarded as ‗of equal importance‘ are instead organised hierarchically, focusing primarily on 
disease and ultimately reflecting the organisation of medical specialities and markets. 
 
How are we to understand this critique of biomedicine which, in many ways, contradicts 
extant analyses of the sciences of ageing? Our thesis is that it is rooted in gerontologists‘ 
complex and fraught relationship to the enterprise of biomedicine as the latter took shape 
during the latter half of the twentieth century. Consequently, in what follows, we document 
diverse attempts to forge some relationship between the biology, medicine and ageing and 
how these enterprises were ultimately incorporated into a biomedical approach that has 
emphasised the medical pathologies of old age, rather than focussing on ageing as a complex 
biological phenomenon. To avoid any misunderstanding, we must emphasise at this point that 
what we are seeking to offer is a genealogy of the present situation, a ‗history of the present‘, 
rather than any account of origins. 
   
Between unity of causes and unity of effects 
Between the late 1930s and early 1950s, a variety of public and private actors became 
interested in the biology of ageing. Underpinned by a burgeoning volume of actuarial 
projections of an ‗ageing population‘ and preoccupation about economic deprivation and 
illness (Haber & Gratton, 1994; Thane, 2000), such interest was not matched however by any 
pre-existent, agreed set of epistemic commitments among the variety of actors studying 
ageing as a strictly biological phenomenon. Instead, it excited a number of debates over the 
definition of ageing which resulted in a diversity of possible answers to the questions posed 
by these public and private actors. Such divergence was particularly evident during the 
conferences supported by two of the most active philanthropic supporters of research on 
ageing, the Josiah Macy Foundation in the United States and the Nuffield Foundation in the 
United Kingdom. 
 
The Josiah Macy Foundation was responsible for funding surveys of ageing in the 1930s and 
commissioning a seminal conference on the biology of ageing at the end of the decade. As 
Park (2008) has documented, Edmund Cowdry‘s edition of the published proceedings of this 
conference was riven by disagreement between the various contributors, mostly around the 
‗parameters‘ and ‗standards‘ by which to contrast normal and pathological ageing. Similarly, 
the Nuffield Foundation was a key sponsor of ageing research and is renowned for having 
sponsored the Survey Committee on the Problems of Ageing and the Care of People, which 
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brought the living conditions of older citizens to the attention of the British public (Thane, 
2000). What is less known is Nuffield Foundation‘s support for research into the biology of 
ageing, which started in 1940 and eventually resulted in an extensive network of laboratories 
across the United Kingdom. Here too, however, the uncertainties were deep and, when the 
Nuffield Foundation sponsored a symposium in 1956 to showcase its achievements in this 
domain, there was conflict between those who wanted to find standards by which to contrast 
normal and pathological ageing and those who considered this endeavour as entirely 
pointless. 
 
The questions of definition raised during these diverse encounters were most clearly 
delineated during the first CIBA Foundation Colloquium on Ageing, which was held in 1954, 
immediately after the first meeting of the International Gerontological Association. The list 
of participants included the leading experts of the day on the biology of ageing. According to 
the published proceedings of the colloquium, following the chairman‘s introduction of the 
concluding, general discussion, Alex Comfort, Nuffield Research Fellow in the Department 
Zoology at University College, London, intervened in the following terms: 
I would like to put in a plea for [Professor Medawar‘s] definition of senescence as 
the increase in liability to die with advancing age. It may be proper to distinguish 
ageing from senescence, but in that case I think we can scrap ageing altogether 
and call it development, because gerontology is an entity which only comes into 
existence to describe a process human beings don‘t like, a deteriorative process, 
and I take it that it is senescence with which we are concerned here.  
Earlier in the meeting Dr. Lansing made a declaration of faith on the subject of the 
overall unity of the senescent process. I don‘t want to speak out of turn, but I‘m 
somewhat sceptical of [the] underlying unity of any ageing process. 
Comfort‘s call for a conventional definition of ‗ageing‘ did not go unchallenged. Albert 
Lansing, from the Department of Anatomy at Washington University, responded: 
But take the male rotifer: it is born, it has no alimentary trait and dies of starvation 
within twenty-four hours after fertilizing. Does he die of senescence? I‘d rather 
put him in a special category, as a very degenerate character who starves to death 
in the twenty-four-hour period that he is busy fertilizing. [...] When I think of 
senescence I think of something that happens not to children or to infant rotifers, 
but to the organism that has become an adult and then undergone some type of 
change, to wind up dead sooner or later. That‘s what I mean by senescence. The 
maturation of the embryo, the new born child, the adolescent, the changes with 
time prior to maturation, to me are not senescence. 
Cowdry: Yours is the downswing of life, then. 
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Lansing: Yes, after adulthood has been reached. I can‘t define adulthood too well, 
and in some cases the changes that occur in adulthood are said to be 
improvements rather than losses. 
Cowdry: You don‘t have to define it if you just call it the downswing, that implies 
that after a height you start to go down. 
Comfort: Do you agree then that for various organisms the factors that contribute 
to that downswing tend to differ very radically from phylum to phylum? 
Lansing: I‘m not prepared to agree to that. I think we have special cases which 
bring about death, but not all death is due to senescence. [...] The declaration of 
faith I made yesterday stems in part from the various types of survival curves that 
Dr. Comfort showed us. [...] It would be quite a coincidence if all these processes 
all expressed themselves in the same way. 
Comfort: Raymond Pearl plotted a survival curve for automobiles which was 
again the same shape!  
At this point, Nathan Shock, the Director of the Gerontology Section of the National Heart 
Institute/National Institutes of Health and effective founder of the International 
Gerontological Association, interjected: 
I think the argument that because two different phenomena can be made to fit the 
same mathematical formulation they have common processes behind them is an 
extremely hazardous one. 
Lansing: I said only that it‘s a possibility, I‘m not prepared to say that we have as 
many kinds of protoplasm as we have species. I think there is common protoplasm 
with basic properties of multiplication and growth, decline, irritability and so on, 
varying in detail, not in principle. 
Shock sought to bring the argument to a close in the following terms: 
I would agree that protoplasm is probably fundamentally much the same stuff, 
although we know that various tissues develop different functions, so that their 
enzyme systems must vary quite widely between different cells in the same 
animal. To that extent, I would agree that perhaps if you knew what it was that 
caused a cell to lose its ability to maintain concentration gradients, maintain its 
metabolic processes, you would be a long way toward understanding the ageing 
process. But it seems to me that the techniques that we have for investigating 
single cells are very meagre. Dr. Cowdry feels that if you take a cell out of its 
tissue it is no longer a cell. If we accept this position we are limited to unicellular 
organisms for study, but unfortunately most of these species simply divide and 
form two new cells so that ‗ageing‘ fails to occur. Thus, we are faced with the 
problem of studying more complex animals or tissue, using both biochemical and 
physiological techniques. Since changes in the environment of the cell, produced 
by changing the diet of the animal, will often result in alterations in cellular 
enzymes, it seems to me that perhaps we are going to have to look at the problem 
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of ageing from a number of different levels simultaneously and not try at the 
moment to conceptualize the entire problem in one framework. Prof. Medawar 
has approached the problem from a statistical evaluation of life tables; I am not 
prepared to accept this approach as the only way out of the difficulties. I think the 
examination of life table might be an index as to what you were doing to a 
process, but if you are going to explain ageing as a process I think ultimately you 
have to look at individuals, and perhaps the best way is to look at them from 
different points of view and at different levels of organization. I doubt if it would 
be possible to formulate a definition of ageing that would be acceptable to 
everybody and would cover all the aspects of the problem as it now stands 
(Wolstenholme & Cameron, 1955: 240-244). 
This debate can be regarded as the confrontation of three different visions of the biology of 
ageing, underpinned by disparate epistemic and political commitments. The first of these was 
that advanced by Comfort and Peter Medawar, Professor of Zoology at University College, 
London. Theirs was the perspective of population geneticists working with life tables and 
relying on evolutionary arguments to explain differences between populations and species. 
On their account, ageing or senescence was an age-specific aggregation of biological 
phenomena that were physiologically unrelated and peculiar to animals protected from the 
rigours of natural selection. This understanding suggests that any interventions they might 
have envisioned would operate at the aggregate, population level. Against this perspective, 
was that of experimental biologists such as Cowdry and Lansing, who relied on particular 
organisms to produce models of physiological phenomena that were assumed to obtain across 
different species. From this perspective, ageing was to be regarded as a unitary phenomenon 
that occurred in all organisms at some point in their developmental cycle and any 
interventions should operate at the cellular level. The third perspective, represented by Shock, 
was firstly that the first two perspectives were epistemologically equivalent, and, secondly, 
that the individual should be regarded as the fundamental biological unit which could then be 
examined ‗from different points of view‘. This programme was to be delivered by 
physiological measurements of the ageing individual in the laboratory, clinic or community 
so as to establish standards of ‗normal ageing‘ and would leave to clinicians the task of 
managing the pathologies of ageing.  
 
Importantly, Shock‘s ability to subsume the first two perspectives and to do so with sufficient 
authority to close the debate, at least temporarily, was not underpinned by some alternative 
disciplinary approach, but by changes happening elsewhere. Shock‘s proposal to embrace 
‗different points of view‘ aimed to integrate gerontology in the institutional transformation 
sparked by the creation of the National Institutes of Health and correlated private and public 
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investments in research programmes on cancer and heart disease that have come to define the 
biomedical enterprise (see Gaudillière, 2002; also Keating & Cambrosio, 2003). It is to the 
project of integrating gerontology with the emerging biomedical enterprise that we now turn. 
 
Coordinating medicine, biology and old age 
There can be little doubt that, during the 1950s and 1960s, Nathan Shock played a pivotal 
role in integrating gerontological research within the changing institutional organisation of 
American medical research, and in aligning gerontology with the normative requirements of 
emergent biomedicine (see Achenbaum, 1995). This was encapsulated primarily in the design 
of the Baltimore Longitudinal Study of Aging (BLSA), which Shock began to develop in the 
mid-1950s to measure individual functional capacity over time (see Bookstein & 
Achenbaum, 1993). Although contemporary with the longitudinal studies which characterised 
American public health research during these years, such as the Framingham Heart Study 
(see Oppenheimer, 2005; Rothstein, 2003), the BLSA was distinctive insofar as it focussed 
on ‗healthy individuals‘ alone, to the exclusion of all those who contracted any illnesses. This 
was due to Shock‘s interest in disentangling ‗pure ageing‘ from ‗disease‘ and so providing 
the standard that would guide geriatricians in their diagnosis and management of old age 
illnesses (Shock, 1956; 1961). This concurred with the aims of geriatricians themselves. 
From the 1940s onward, American geriatrics aimed to establish itself within medical 
specialities, and, as Hirshbein (2000) has suggested, this was achieved by evoking a notion of 
normal ageing and then defining the expertise of the geriatrician as dealing with the 
prevention and treatment of diseases of old age. Gerontology, particularly the physiological 
and functional measurement provided by case-controlled or longitudinal studies such as those 
that Shock proposed, was construed as providing the requisite biological standards. 
Importantly, Shock‘s distinction between normal and pathological ageing served not only 
clinical, but also political goals when the plan to establish a national programme of research 
into the causes of the diseases commonly associated with old age finally moved onto the 
national political agenda and was constructed on this same distinction (Achenbaum, 1995). 
Equally importantly, while the distinction would appear to have enabled a hybrid 
understanding of normal ageing that was workable in the clinic and the laboratory, the 
development of gerontology was constrained by its institutional association with the 
Veterans‘ Administration (VA) (Haber, 1986; Achenbaum, 1995) such that it was only when 
the claims advanced by ever larger numbers of ageing veterans started to strain the VA‘s 
resources that the calls to establish a national programme of research into the causes of the 
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diseases associated with old age gained any political support. In other words, the solidity of 
the alignment between Shock and the nascent National Institute of Ageing (NIA) should not 
be overestimated and it perhaps is no surprise that, despite Shock‘s ambitions to create a 
national programme of research that might help to differentiate healthy from unhealthy 
ageing, the NIA only secured a firm political foothold when it began consistently to sponsor 
research on what, at least according to Robert Butler, has today has become the defining 
disease of old age, Alzheimer‘s Disease (AD) (Anon., 2008; see also Ballenger, 2006). 
 
In the United Kingdom, a different configuration of medicine, biology and old age not only 
distanced gerontology from biology altogether, but resulted ultimately in the significant 
weakening of gerontology as an autonomous discipline. Some of the reasons for this fate are 
most evident by comparing the disciplinary affiliations of the participants in the CIBA 
Foundation Colloquium and the Nuffield Trust conference on the ‗biology of ageing‘. While 
no social scientists appear to have been invited to attend the CIBA Foundation Symposium, 
other than in an honorary capacity, the conference funded by the Nuffield Trust was 
organised by, and attracted, a very diverse group of experts, some being either zoologists or 
botanists and others being either clinicians, psychologists or economists. The challenge was 
then to establish how their diverse expertise might be coordinated so as to address the social 
and political question posed by ageing. This situation is not surprising given that the Nuffield 
Foundation was renowned firstly as the sponsor of the Survey Committee on the Problems of 
Ageing and the Care of People and that, in the absence of any substantial, structured funding 
by the Medical Research Council (MRC) for research on the biology of ageing, the Nuffield 
Foundation supported a variety of academic programmes that relied on equally varied 
methods, though focussing primarily on the importance of social and economic conditions to 
the definition of ‗normal‘ ageing. Furthermore, as Martin (1995) has observed, it was not 
through the laboratory but ‗through the technique of the survey [that] doctors created a body 
of knowledge relating to the social, economic, and medical needs of the aged population in 
their own districts‘ (458). In the process, British geriatricians defined gerontology as the 
field, in Lord Amulree‘s words, concerned with ‗those elderly sick with social and economic 
problems‘ (460; our italics). Importantly, this construction positioned gerontology outside the 
hospital, the main research platform of British biomedicine during the second half of the 
twentieth century (Stewart, 2008). Furthermore, the consequent association between the old 
age and that peculiarly British disciplinary integration of social and medical science that went 
by the name of ‗social medicine‘ was responsible for much uncertainty around the place of 
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the elderly within the National Health Service (NHS). Under these circumstances, any 
funding for research on the medical problems posed by older people tended to be allocated to 
disease specific programmes within the MRC because there seemed to be nothing so 
biologically and clinically distinctive and remarkable about the patients‘ chronological age as 
to deserve the attention of a specialist (see also Ballenger, 2006). Finally, in the 1960s and 
1970s, when social medicine lost its precarious institutional support within both the MRC and 
NHS (Porter, 1997), British gerontology lost all residual disciplinary legitimacy. Thus, 
despite the fact that at the time of the CIBA Foundation Colloquium the evolutionary 
perspective on ageing was a wholly British and very vibrant current, institutional and political 
factors had worked together to progressively disconnect biological explanations of ageing 
from any public debates and programmes to address the ‗problem of old age‘ so that Peter 
Medawar could declare in 1977 that British gerontology was moribund and that ‗those 
anxious about the possible malefactions of research on ageing should take comfort from the 
fact that the great public and private agencies are not competing with each other in their 
endeavours to support research on ageing‘ (Medawar & Medawar, 1977: 159). 
 
In sum, if the ‗problem of old age‘ emerged during the years between the late 1930s and early 
1950s as a pressing political question and a variety of powerful institutions became interested 
in the biology of ageing, the successful alignment of ageing, biology and medicine was a 
highly contingent and unstable affair. 
 
The trouble with the National Institute of Aging 
It is widely acknowledged that the establishment of the National Institute of Aging (NIA) was 
a difficult and protracted matter. Importantly, while the difficulties have been portrayed as a 
matter of divergence between gerontologists and the medical establishment (Lockett, 1983), 
there also is evidence of divergence among gerontologists themselves over the framing of a 
coordinated programme of research on the biological origins of ageing.  
 
Between 1963 and 1965, Leonard Hayflick, a cytologist working in the expansive domain of 
experimental oncology, challenged the notion that cell lines were potentially immortal by 
demonstrating that the number of replications cells could undergo was limited and that the 
limit was fixed by cellular mechanisms that were eventually located within the nucleus 
(Landecker, 2007). The challenge went unnoticed among oncologists because the notion that 
cell lines were potentially immortal was too solidly embedded in the material practices of 
Page | 12 
 
experimental oncology, but it did not go unnoticed among gerontologists insofar as it offered 
scope to rearticulate and revitalise Edmund Cowdry‘s experimental approach to ageing. This 
interest came to a head in 1973, when Hayflick received the Robert Kleemeier Award, which 
the Gerontological Society of America bestowed annually ‗in recognition of outstanding 
research in the field of gerontology‘. In his acceptance lecture, Hayflick (1974), while 
admitting feeling ‗somewhat uncomfortable in accepting an award for work which at the 
outset was undertaken with the biology of aging farthest from [his] mind‘ (37), was quick to 
propose the following: 
What are the implications to gerontologists of the notions that are emerging from 
cytogerontology? I believe that there are several important implications. The first 
is that the primary causes of age changes can no longer be thought of as resulting 
from events occurring at the supracellular level, i.e., at cell hierarchies from the 
tissue level and greater. The cell is where the gerontological action lies. I believe 
therefore that purely descriptive studies done at the tissue, organ and whole 
animal level, as they pertain to the biology of aging, are less likely to yield 
important information on mechanism than studies done at the cell and molecular 
level (39; our italics). 
In other words, according to Hayflick, investigations of ageing would be most productive 
when grounded in the methods of ‗cytogerontology‘, the new field of research which 
Hayflick himself was busy trying to define and delineate, but he also seemed intent on 
challenging Shock‘s programme for the development of gerontology, firstly because Shock 
had justified his focus on individuals on the grounds that the cellular level concerned only a 
subset of the gerontological phenomena and secondly because the list of ‗purely descriptive 
studies‘ of ageing presumably included the Baltimore Longitudinal Study of Aging (see also 
Achenbaum, 1995). There was more, however. If Shock‘s programme was underpinned by 
the need to distinguish between normal and pathological aging, on Hayflick‘s vision this 
would become a problematic endeavour:  
One is forced to conclude that if all disease related causes of death were to be 
resolved, then the aging processes would present some clear physical 
manifestations well in advance of death itself. The challenge, of course, is to 
separate disease-related changes from the basic biological changes that are a part 
of the aging process. Since fundamental aging processes most certainly contribute 
to or allow for the expression of pathology, then the two concepts may be so 
closely intertwined as to make any clear distinctions a futile exercise in semantics 
(43). 
The question about the relationship between the normal and pathological which Hayflick thus 
posed rested explicitly on Alex Comfort‘s well-established evolutionary explanation of 
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ageing (see Moreira & Palladino, 2008). Natural selection, Comfort argued, operated most 
forcefully on those phases of the life cycle which were related to reproduction, so that the 
expression of any deleterious mutations in these phases would be targeted more strongly than 
their expression in post-reproductive phases. This, according to Comfort, led to an 
accumulation of deleterious genes whose expression occurred in the later phases of the life 
cycle, eventually resulting in the genetic determination of the post-reproductive weakening of 
the organism commonly named ‗ageing‘. From this evolutionary perspective, seeking to 
‗separate disease-related changes from the basic biological changes that are a part of the 
aging process‘ was questionable, to say the least. Significantly, just two years after these 
critical declarations, Hayflick was mentioned as a possible first director of the NIA, thus 
illustrating the force of his criticism of Shock‘s programme, but Hayflick‘s accompanying 
ambition to totally reconfigure the organisation of gerontological research may also have 
been the reason for its limited institutionalisation. Thus, the first director of the NIA was not 
Hayflick, but Robert Butler, psychologist and author of the best-selling and prize-winning 
book Why Survive? Growing Old in America (1975) (see also Ballenger, 2006).  
 
One of the greatest challenges confronting Butler upon his appointment was the lack of 
research capacity and limited public interest in gerontology. Despite Butler‘s attempts to 
enrol policy makers and congressional committees, the NIA struggled to secure any steady 
stream of resources. Thus, when he suggested that ‗research on aging has shifted from its 
exclusive disease orientation toward a more comprehensive investigation of the normal, 
physiological changes with age‘ (Butler, 1977: 8; our italics), the evocation of normality was 
related more to the need to rearticulate how the American public viewed older people‘s role 
in society, than to the needs of clinicians working with older people. The situation only 
changed with the emergence of what Butler called the ‗health politics of anguish‘ (Fox, 1989: 
82), an alliance of activists, clinicians and politicians who called public attention to the 
abandonment experienced by sufferers of senile dementia and those around them. This 
resulted in the prioritisation of research into the causes and treatment of Alzheimer‘s Disease 
(AD), particularly through the NIA‘s extramural research programme, which embodied 
emerging, competition-driven innovation policies that were based on both collaborations 
between universities and pharmaceutical companies and ideals of ‗rational‘ therapeutic 
development from bench to bedside (Moreira, 2009). It should be noted, that, despite Butler‘s 
later disenchantment with the direction taken by the NIA, his own programme for the 
development of gerontology could be said to have facilitated the change insofar as it rested 
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on the transformation of individual failures to adapt and age ‗successfully‘ from a matter of 
psychic disposition into a matter of organic pathology (Ballenger, 2003). More importantly, 
however, with the support thus gained, the NIA experienced an extraordinary influx of 
researchers from other areas of biomedical research. This helped to transform the NIA‘s place 
in the American polity, but in the form of a highly visible disease-specific programme that 
eventually accounted for the majority of NIA‘s budget. This caused considerable 
dissatisfaction among a number of gerontologists. As Richard Miller (2002) has noted, and 
plaintively so, ‗senators‘ and voters‘ parents [die] of specific diseases‘ and are less likely to 
fund a general, ‗basic‘ programme of research on ageing. In sum, AD firmly established the 
position of the NIA within the political and clinical worlds, but only by emphasising the 
equation of ageing and illness. If gerontologists such as Butler, Hayflick and Miller felt that 
an opportunity had been a missed, however, this situation also created the conditions for an 
unlikely alliance between programmes aiming to distinguish between normal and 
pathological ageing, on the one hand, and investigations of ageing at the cellular and sub-
cellular level, on the other hand.  
 
Biogerontology and the promise of health 
During the 1990s, the alignment of evolutionary models and genetic research which Richard 
Dawkins‘s Selfish Gene (1976) had by then popularised very successfully renewed 
gerontologists‘ interest in the evolutionary understanding of ageing, especially because it 
seemed to promise a new articulation of the problem of old age and how to address them (see 
also Nesse & Williams, 1996). This is powerfully illustrated by the increasing importance 
attached to Thomas Kirkwood‘s work.  
 
Kirkwood (1977) rearticulated Alex Comfort‘s evolutionary explanation by combining 
molecular and demographic analyses to advance the notion that the organism should be 
understood as the product of a historical process involving the balancing of energetic 
investments in the somatic body, to enhance the chances of successful reproduction of the 
germinal line, and the cost of these investments to the continuity of the germinal line. On this 
understanding of ageing, attention is then directed toward the molecular mechanisms 
involved in the preservation of genomic integrity, or, as Kirkwood has put it, toward ‗the 
evolved capacity of somatic cells to carry out effective maintenance and repair‘ (Kirkwood & 
Austad, 2000: 235). Importantly, in this new vision, the business of gerontology becomes to 
enhance the ability of the individual to approximate the immortal germinal line, even if 
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immortality itself is irretrievably denied by the evolutionary history of the human species. 
The hope is that this redefinition will at least result in maximising the biological functionality 
of the individual up to the moment of death. Thus conceived, gerontology ceases to be a field 
of clinical specialisation concerned with the diseases of a distinct population, the elderly, as 
these diseases are rearticulated as unfolding temporally onto antecedent risk factors and 
biomolecular pathways. Biomolecular and demographic pathways of individuals who might 
be ‗at risk‘ of developing pathologies such as cardio-vascular disease, cancer and dementia 
are traced backward, to the earliest possible molecular, behavioural or clinical manifestations, 
aiming to develop multiple preventative interventions. These pathologies thus become part of 
a wider set of ‗degenerative diseases‘ that are only connected contingently to the organism‘s 
chronological age. Within this framework, all degenerative diseases might be said to entail 
‗ageing‘, but in so expanding its domain of application the term ‗ageing‘ no longer identifies 
a distinct biological process of its own kind. Equally importantly, because the domain of 
gerontology thus defined is resistive to any precise delimitation, it can become an object of 
interest for all clinical practitioners involved in managing degenerative diseases, from the 
primary care practitioners controlling middle-age hypertension to the specialised clinicians 
required to train these practitioners in the assessment of the earliest symptoms of cardio-
vascular weakening. Furthermore, gerontology also offers opportunities of development to a 
great variety of actors in the market for health care as investigation of the mechanisms 
involved in the onset of these degenerative diseases greatly expands opportunities for 
pharmaceutical companies because the threshold of treatment moves ever backward to 
encompass a greater fraction of the population. This said, the investigation of these same 
mechanisms also offers opportunities to those providing the wherewithal and support to 
secure ‗healthy lifestyles‘ from birth to death. In so doing, biogerontology promises to deliver 
a central expectation of private and public health care insurers, namely reducing the 
prevalence of degenerative diseases so as to reduce the aggregate cost of provision. 
 
Importantly, by drawing on evolutionary biology to explore organisms‘ life histories in 
relation to the genome and the environment, the biogerontological programme enables links 
between the laboratory, preventative medicine and health maintenance programmes. One of 
the key changes in the organisation of research, clinical practice and policy at the end of the 
twentieth century has been the shift from the ‗problem of disease‘ to the ‗problem of health‘. 
This entails not only constructing an understanding of the molecular, individual and social 
dynamics that lead to illness, rather than just focussing on restoring health, but also reliance 
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on preventative therapeutic strategies and health promotion programmes. These in turn are 
sustained by enhanced surveillance technologies which regulate access to therapies and 
programmes by identifying risk factors or states and supporting individuals‘ re-organisation 
of their conduct in light of such risks (Clarke et al., 2003; May et al., 2006; Rose, 2007). 
Significantly, in so doing, biogerontologists differentiate themselves from the ‗anti-ageing‘ 
movement and medicine (Olshansky et al., 2002; see also Juengst et al., 2003 and Fishman et 
al., 2008). While the latter argue for an interventionist approach to ageing, ageing being 
conceived in this case as a ‗natural‘, but ‗modifiable‘, process (Mykytyn, 2008), 
biogerontologists suggest that there is in fact nothing ‗natural‘ about ageing. Instead, the 
plasticity of the human organism, and in particular how first death and then ageing have been 
significantly postponed during the last few centuries, is where biogerontologists draw support 
to propose the further expansion of public health measures to further this historical process. 
Consequently, in a recent public statement, a number of influential biogerontologists and 
representatives of non-governmental charitable organisations have argued that ‗the 
exploration of the mechanisms by which ageing can be postponed in laboratory models will 
yield new models of preventive medicine and health maintenance for people throughout life, 
and the same research will also inform a deeper understanding of how established 
interventions, such as exercise and healthy nutrition, contribute to lifelong wellbeing‘ (Butler 
et al., 2008: 399). In so doing, they call upon individuals identified through screening 
programmes and characterised through a variety of molecular and demographic markers to 
produce and maintain their own health. Such promise of health can only be realised however 
if research policies provide the means to focus on the basic biology of ageing and abandon 
biomedicine and its disease-driven business.  
 
Conclusion 
During the past decade, discontent with the organisation of research into the causes and 
treatment of diseases associated with age has motivated highly visible public debates in both 
the United States and the United Kingdom. In this context, a number of influential 
biogerontologists have offered an alternative to disease-specific programmes which calls into 
question both biomedicine and the historical opposition between biomedicine and public 
health. Such proposals, as we have argued elsewhere, could be taken as evidence of a 
transformation of socio-political forms of management whereby ‗the individual of the 19th 
century biopolitical imaginary, a human body whose biological constitution was irremediably 
fixed at birth, is giving way to an understanding of the human body as an assembly of 
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biomolecular components that can be […] recombined so as to maximize the resultant unit‘s 
cultural, social and political productivity‘ (Moreira & Palladino, 2008: 21). Whether and how 
the proposed link between the laboratory, preventative medicine and health maintenance 
programmes will work in practice is however a matter of empirical case studies of the 
development, mediation and use of emerging gerontological technologies. Furthermore, as 
we have argued in this paper, such studies should not be underpinned by a critical appraisal 
of biogerontology as a ‗biomedicalization of ageing‘ because biogerontology positions itself 
outside the institutions of biomedicine. In other words, the challenge for future studies will be 
to understand how the current uncertainties of the biogerontological programme play out in 
multiple social and political arenas. 
 
Finally, some of the uncertainty involved in the future development of the biogerontological 
programme is evident in the reluctance with which the British government has greeted some 
of the recommendations advanced in the House of Lords Report on Ageing (2005). The 
Science and Technology Committee of the House of Lords was particularly surprised that it 
was not the Science Secretary who responded to its report, a report on the ‗scientific aspects 
of ageing‘ (our italics), but the Minister for Work and Pensions, who argued that ‗old age‘ 
had long been a major concern of the Government and that it had already invested very 
heavily in the improvement of health and social care, as well as pensions. Citing a 
memorandum by one of the chief scientific advisors involved in the preparation of the report, 
Thomas Kirkwood, the Science and Technology Committee wrote:  
It is particularly disappointing that the Government seem to wish to ‗pigeon-hole‘ 
ageing research, as if ageing were an isolated, discrete problem, and that research 
into ageing must necessarily compete with research into other areas. Thus the 
response reproduces the familiar mantra that ‗given finite resources, there will 
always be a need to balance competing priorities for research‘. As we sought to 
demonstrate in our Report—a point repeated by Professor Kirkwood in his written 
comments—ageing is a continuum, affecting all of us all the time. He also 
reiterates the point made in our Report, that generic research into the process of 
ageing, far from being in competition with research into specific conditions 
affecting older people, may be ‗the most direct route to developing novel 
interventions and therapies‘. There is no sign of such holistic thinking in the 
Government response (House of Lords, 2006a). 
The Science and Technology Committee‘s contrast between ‗specific conditions affecting 
older people‘ and the notion that ‗ageing is a continuum, affecting all of us all the time‘ was 
informed by Kirkwood‘s more specific observation that, ‗there are scientific connections 
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between birth, early years, childhood and adolescence that have major impacts on health and 
quality of life in middle and old age. These need much greater attention ...‘ (House of Lords, 
2006b). What might explain the Department of Work and Pensions‘ rejection of the House of 
Lords‘ recommendations may be that the Department remains committed to the needs of a 
specific subset of the population, the chronologically aged and their distinctive social 
problems. If this surmise is correct, it indicates that there are significant obstacles to the 
biogerontological programme and that they stem from the coexistence of biopolitical and 
disciplinary modes of governance.  
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Notes
 
1
 Defining biogerontology, especially in relation to the ‗anti-ageing‘ movement and medicine, 
is fraught with difficulties and ambiguities (Juengst et al. 2003; Fishman et al. 2008), but we 
hope that the account we provide here goes some way toward clarifying differences. 
2
 The interview was conducted in the context of the ESRC funded project ‗Boundary work, 
normal ageing and brain pathology‘. 
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